{
    "clinical_study": {
        "@rank": "63965", 
        "arm_group": [
            {
                "arm_group_label": "DCVAC/OvCa with Standard of Care", 
                "arm_group_type": "Experimental", 
                "description": "DCVAC/OvCa in parallel with chemotherapy (Standard of Care)"
            }, 
            {
                "arm_group_label": "DCVAC/OvCa sequentially chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "DCVAC/OvCa sequentially after chemotherapy"
            }, 
            {
                "arm_group_label": "Standart of Care", 
                "arm_group_type": "Active Comparator", 
                "description": "Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether DCVAC/OvCa  added to Standard of Care\n      chemotherapy (carboplatin plus paclitaxel as first line chemotherapy) may result in\n      prolongation of progression free survival (PFS)."
        }, 
        "brief_title": "Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ovarian Neoplasms", 
            "Ovarian Epithelial Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma", 
                "Ovarian Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female aged \u226518 years\n\n          -  Patients with newly diagnosed, histologically confirmed, International Federation of\n             Gynecology and Obstetrics (FIGO) stage III epithelial ovarian, primary peritoneal or\n             fallopian tube carcinoma (serous, endometrioid or mucinous) who have undergone\n             initial surgery up to 3 weeks before randomization and are selected to receive first\n             line Standard of Care chemotherapy (optional prolongation to 6 weeks after surgery)\n\n          -  Optimally debulked (zero residuum) or maximal residuum <1cm\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0,1,2\n\n        Exclusion Criteria:\n\n          -  FIGO I,II,IV epithelial ovarian cancer\n\n          -  FIGO III clear cells epithelial ovarian cancer\n\n          -  Non-epithelial ovarian cancer (OvCa), borderline tumors (tumors of low malignant\n             potential)\n\n          -  Post-surgery residual disease with lesion(s) >1cm\n\n          -  Prior or current systemic anti-cancer therapy for ovarian cancer [for example\n             chemotherapy, monoclonal antibody therapy (bevacizumab), tyrosine kinase inhibitor\n             therapy, vascular endothelial growth factor (VEGF) therapy or hormonal therapy]\n\n          -  Previous or concurrent radiotherapy to the abdomen and pelvis\n\n          -  Malignancy other than epithelial ovarian cancer, except those that have been in\n             clinical remission (CR) for a minimum of 3 years, and except carcinoma in-situ of the\n             cervix or non-melanoma skin carcinomas\n\n          -  Patient co-morbidities:Human immunodeficiency virus (HIV) positive, human\n             T-lymphotropic virus (HTLV) positive, Active hepatitis B (HBV), active hepatitis C\n             (HCV), active syphilis\n\n          -  Evidence of active bacterial, viral or fungal infection requiring systemic treatment\n\n          -  Clinically significant cardiovascular disease including:\n\n        Symptomatic congestive heart failure Unstable angina pectoris Serious cardiac arrhythmia\n        requiring medication Uncontrolled hypertension Myocardial infarction or ventricular\n        arrhythmia or stroke within a 6 month period before inclusion, ejection fraction (EF) < 40\n        percent or serious cardiac conduction system disorders, if a pacemaker is not present"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107937", 
            "org_study_id": "SOV01", 
            "secondary_id": "2013-001322-26"
        }, 
        "intervention": [
            {
                "arm_group_label": "DCVAC/OvCa with Standard of Care", 
                "description": "DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel", 
                "intervention_name": "DCVAC/OvCa with Standard of Care", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Carboplatin", 
                    "Paclitaxel"
                ]
            }, 
            {
                "arm_group_label": "DCVAC/OvCa sequentially chemotherapy", 
                "description": "DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel", 
                "intervention_name": "DCVAC/OvCa sequentially chemotherapy", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Carboplatin", 
                    "Paclitaxel"
                ]
            }, 
            {
                "arm_group_label": "Standart of Care", 
                "description": "Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy", 
                "intervention_name": "Standard of Care", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Carboplatin", 
                    "Paclitaxel"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "serous", 
            "endometrioid", 
            "mucinous", 
            "epithelial ovarian cancer"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic", 
                        "zip": "625 00"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic", 
                        "zip": "656 53"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hradec Kr\u00e1lov\u00e9", 
                        "country": "Czech Republic", 
                        "zip": "500 05"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olomouc", 
                        "country": "Czech Republic", 
                        "zip": "775 20"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ostrava", 
                        "country": "Czech Republic", 
                        "zip": "708 52"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha", 
                        "country": "Czech Republic", 
                        "zip": "128 08"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 5", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "\u010cesk\u00e9 Bud\u011bjovice", 
                        "country": "Czech Republic", 
                        "zip": "370 01"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01465"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany", 
                        "zip": "91054"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany", 
                        "zip": "50931"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bialystok", 
                        "country": "Poland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bialystok", 
                        "country": "Poland", 
                        "zip": "15-276"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland", 
                        "zip": "31-501"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poznan", 
                        "country": "Poland", 
                        "zip": "60-569"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "Germany", 
                "Poland"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Open-label, Three-arm, Multi-center Phase II Trial of Addition of DCVAC/OvCa to First Line Standard Chemotherapy in Women With Newly Diagnosed Epithelial Ovarian Carcinoma", 
        "overall_contact": {
            "email": "kapsa@sotio.com", 
            "last_name": "Richard Kapsa", 
            "phone": ": (+420) 2241 74448"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "European Union: European Medicines Agency", 
                "Czech Republic: State Institute for Drug Control", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Germany: Paul-Ehrlich-Institut"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall progression free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "104 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107937"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of patients in remission after first line chemotherapy at 6 months", 
                "safety_issue": "No", 
                "time_frame": "0,10, 18, 30, 42 weeks"
            }, 
            {
                "measure": "Proportion of patients in remission after first line chemotherapy at 12 months", 
                "safety_issue": "No", 
                "time_frame": "0,10, 18, 30, 42, 54, 68, 80, 92, 104 weeks"
            }, 
            {
                "measure": "Biological progression free interval", 
                "safety_issue": "No", 
                "time_frame": "0,10, 18, 30, 42, 54, 68, 80, 92, 104 weeks"
            }, 
            {
                "measure": "Immunological Response", 
                "safety_issue": "No", 
                "time_frame": "0, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 54, 60 weeks"
            }, 
            {
                "measure": "Proportion of patients requiring 2nd line chemotherapy", 
                "safety_issue": "No", 
                "time_frame": "0, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 21, 24, 27, 30, 36, 42, 48, 54, 60, 64, 68, 74, 80, 86, 92, 98, 104 weeks"
            }, 
            {
                "measure": "Frequency of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "0, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 21, 24, 27, 30, 36, 42, 48, 54, 60, 64, 68, 74, 80, 86, 92, 98, 104 weeks"
            }, 
            {
                "measure": "Time to 50 percent survival", 
                "safety_issue": "No", 
                "time_frame": "0, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 21, 24, 27, 30, 36, 42, 48, 54, 60, 64, 68, 74, 80, 86, 92, 98, 104 weeks"
            }
        ], 
        "source": "Sotio a.s.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sotio a.s.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}